Last updated: 2026-09-05 12:46:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
NeOnc Technologies Holdings, Inc. (NTHI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $5.04, with a market capitalization of $128.64M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.01 to $12.99. This page covers its latest market performance, valuation, price trends and company information.
$128.64M | |
$4.76 | |
$25.00 | |
$3.01 | |
$4.79 | |
99.57K | |
-- | |
-- | |
$12.99 | |
$3.01 | |
-- | |
-- |
NeOnc Technologies Holdings, Inc. (NTHI) last closed at $4.79 as of 2026-09-04 23:58:00, unchanged from the previous close of $4.79.
During the latest regular trading session, NTHI traded between $3.01 and $25.00, with a volume of 99.57K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, NeOnc Technologies Holdings, Inc. (NTHI) moved from $4.74 to $5.04, representing a gain of 6.33% ($0.30).
The stock traded between $4.76 and $5.22 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 124.17 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 20.4%
NTHI is currently trading at $5.04, placing it 20.4% of the way from its 52-week low of $3.01 to its 52-week high of $12.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NeOnc Technologies Holdings, Inc. (NTHI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.